Markets
News
Analysis
User
24/7
Economic Calendar
Education
Data
- Names
- Latest
- Prev
Trending
Indices
US
Crypto
Forex
Commodities
Futures
SYMBOL
LAST
NET CHG.
%CHG.
HIGH
LOW
- All
- Chatrooms
- Groups
- Friends
Connecting
.
.
.
US
VN
TW
- All
- US Election
- Israel-Palestine Conflict
- Russia-Ukraine Conflict
Search
News
Trending Topics
Daily News
To quickly learn market dynamics and follow market focuses in 15 min.
Remarks of Officials
In the world of mankind, there will not be a statement without any position, nor a remark without any purpose.
Central Bank
Inflation, exchange rates, and the economy shape the policy decisions of central banks; the attitudes and words of central bank officials also influence the actions of market traders.
Forex
Money makes the world go round and currency is a permanent commodity. The forex market is full of surprises and expectations.
Latest Update
Risk Warning on Trading HK Stocks
Despite Hong Kong's robust legal and regulatory framework, its stock market still faces unique risks and challenges, such as currency fluctuations due to the Hong Kong dollar's peg to the US dollar and the impact of mainland China's policy changes and economic conditions on Hong Kong stocks.
HK Stock Trading Fees and Taxation
Trading costs in the Hong Kong stock market include transaction fees, stamp duty, settlement charges, and currency conversion fees for foreign investors. Additionally, taxes may apply based on local regulations.
HK Non-Essential Consumer Goods Industry
The Hong Kong stock market encompasses non-essential consumption sectors like automotive, education, tourism, catering, and apparel. Of the 643 listed companies, 35% are mainland Chinese, making up 65% of the total market capitalization. Thus, it's heavily influenced by the Chinese economy.
HK Real Estate Industry
In recent years, the real estate and construction sector's share in the Hong Kong stock index has notably decreased. Nevertheless, as of 2022, it retains around 10% market share, covering real estate development, construction engineering, investment, and property management.
Recent Searches
Top Searches
View All
No data
Search
United-Guardian Reports Y/Y Rise in Q3 Earnings, Flat Revenues
Zacks
United-Guardian, Inc. UG reported strong results for third-quarter 2024, demonstrating its resilience through growth in key product segments and effective cost management. With stable revenues across its portfolio, UG has effectively navigated challenges in its pharmaceutical operations while capitalizing on rising demand within the cosmetics market. The company's commitment to innovation and operational efficiency has bolstered profitability, positioning United-Guardian for sustained growth as it anticipates a rebound in its pharmaceutical segment.
Q3 Results
United-Guardian reported a modest 35.7% increase in its third-quarter 2024 earnings per share of 19 cents from 14 cents in the prior-year quarter.
The company’s total quarterly sales were $3.06 million, unchanged from the year-ago quarter.
Quarterly earnings can be attributed primarily to effective cost management and increased demand for its cosmetic ingredients segment.
United-Guardian, Inc. Price, Consensus and EPS Surprise
United-Guardian, Inc. price-consensus-eps-surprise-chart | United-Guardian, Inc. Quote
Disaggregated Sales by Products
Cosmetic Ingredients: This segment posted 8% year-over-year sales growth. The rise was driven by increased orders from United-Guardian's largest cosmetic distributor, highlighting a sustained product demand.
Medical Lubricants: Sales in this category dipped 2% year over year, attributed to standard fluctuations in order patterns, reflecting the segment’s variability.
Pharmaceutical Products: The pharmaceutical segment’s sales dropped 6% from third-quarter 2023. This was partly due to the ongoing effects of a supply disruption at a contract manufacturer that impacted the production of Renacidin — a flagship pharmaceutical product. Despite this, the company is optimistic about a recovery in this segment as supply stabilizes.
Profitability Metrics
United-Guardian’s operating income rose 31.5% to $0.95 million in the third quarter of 2024 from $0.72 million in the year-ago quarter. Total other income improved from $65,325 in third-quarter 2023 to $147,157 in the reported quarter, driven by a gain on marketable securities and higher investment income.
After accounting for taxes, net income reached $0.9 million, marking a 38% increase from $0.6 million in the prior-year quarter. This improvement was achieved despite flat sales.
Cost Analysis
Total costs and expenses for the third quarter of 2024 declined to $2.1 million from $2.3 million in the prior-year period. Key contributors to this reduction were the cost of sales, which decreased significantly to $1.4 million from $1.7 million.
Operating expenses increased to $0.6 million from $0.5 million, indicating higher spending on operational needs. Research and development expenses also saw an uptick, reaching $0.1 million from $98,141. This investment signals a commitment to innovation, particularly in segments like cosmetics and pharmaceuticals, wherein product development could enhance sales.
Management View
Management suggested optimism about sales growth as production issues surrounding Renacidin are resolved. This resolution could positively impact revenues from pharmaceutical products in subsequent quarters.
Conclusion
United-Guardian's third-quarter 2024 results reflect stable revenues, substantial earnings growth and improved cost management. With rising cosmetic ingredient sales and anticipated recovery in pharmaceuticals, the company appears positioned for steady performance, although it remains sensitive to operational and order pattern fluctuations across segments.
Zacks Investment Research
Risk Warnings and Disclaimers
You understand and acknowledge that there is a high degree of risk involved in trading. Following any strategies or investment methods may lead to potential losses. The content on the site is provided by our contributors and analysts for information purposes only. You are solely responsible for determining whether any trading assets, securities, strategy, or any other product is suitable for investing based on your own investment objectives and financial situation.
Copyright © 2024 FastBull Ltd
728 RM B 7/F GEE LOK IND BLDG NO 34 HUNG TO RD KWUN TONG KLN HONG KONG
Risk Disclosure
The risk of loss in trading financial instruments such as stocks, FX, commodities, futures, bonds, ETFs and crypto can be substantial. You may sustain a total loss of the funds that you deposit with your broker. Therefore, you should carefully consider whether such trading is suitable for you in light of your circumstances and financial resources.
No decision to invest should be made without thoroughly conducting due diligence by yourself or consulting with your financial advisors. Our web content might not suit you since we don't know your financial conditions and investment needs. Our financial information might have latency or contain inaccuracy, so you should be fully responsible for any of your trading and investment decisions. The company will not be responsible for your capital loss.
Without getting permission from the website, you are not allowed to copy the website's graphics, texts, or trademarks. Intellectual property rights in the content or data incorporated into this website belong to its providers and exchange merchants.